Kuros Biosciences received FDA clearance to market the Kuros Transforaminal Lumbar Interbody Fusion cage. The device is to be used with KUR-113, the company’s Fibrin-PTH product candidate for spinal fusion. Clinical trials of the system will now commence.
The cage is available in a range of sizes and cleared for use in the lumbar spine in combination with autograft and/or allograft.
Kuros Biosciences received FDA clearance to market the Kuros Transforaminal Lumbar Interbody Fusion cage. The device is to be used with KUR-113, the company's Fibrin-PTH product candidate for spinal fusion. Clinical trials of the system will now commence.
The cage is available in a range of sizes and cleared for...
Kuros Biosciences received FDA clearance to market the Kuros Transforaminal Lumbar Interbody Fusion cage. The device is to be used with KUR-113, the company’s Fibrin-PTH product candidate for spinal fusion. Clinical trials of the system will now commence.
The cage is available in a range of sizes and cleared for use in the lumbar spine in combination with autograft and/or allograft.
Copy to clipboard 
